Based on changes in coverage, we will stop research coverage of the following companies starting today, and past ratings and target price information will no longer be valid. Details of the current price (as of January 25, 2022) and the date of publication of the last report, ratings and target prices are as follows:
Dongyao Pharmaceutical (1875.HK)
Last report:
2021-08-16 /1H21 Results: CDMO performed well, TAA013 phase III clinical progress/ “buy” rating/target price of HK$9.5
